Gyala Therapeutics is a startup based in Spain.
Gyala Therapeutics is developing GYA01, a CAR-T cell therapy for hematologic cancers including acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL), and is currently conducting Phase I/IIa clinical trials.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.